CD274 and non-small cell lung carcinoma: A retrospective analysis of 52 patients with stage III NSCLC treated with chemoradiotherapy followed by maintenance with durvalumab, like in the PACIFIC trial, showed that patients with PD-L1 expression ≥50% had a lower chance of disease progression and a better OS.(33)